6949 Stock Overview
A biomedical company, engages in the development of cell culture technologies and techniques for therapeutic applications.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Pell Bio-Med Technology Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NT$106.00 |
52 Week High | NT$178.50 |
52 Week Low | NT$70.60 |
Beta | 0 |
11 Month Change | -9.40% |
3 Month Change | -29.80% |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 2.91% |
Recent News & Updates
Shareholder Returns
6949 | TW Biotechs | TW Market | |
---|---|---|---|
7D | 3.4% | 1.4% | 4.2% |
1Y | n/a | 11.5% | 35.3% |
Return vs Industry: Insufficient data to determine how 6949 performed against the TW Biotechs industry.
Return vs Market: Insufficient data to determine how 6949 performed against the TW Market.
Price Volatility
6949 volatility | |
---|---|
6949 Average Weekly Movement | 6.5% |
Biotechs Industry Average Movement | 6.2% |
Market Average Movement | 5.7% |
10% most volatile stocks in TW Market | 9.4% |
10% least volatile stocks in TW Market | 3.0% |
Stable Share Price: 6949's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 6949's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2017 | 88 | Cheng Long Lin | www.pellbmt.com |
Pell Bio-Med Technology Co., Ltd., a biomedical company, engages in the development of cell culture technologies and techniques for therapeutic applications. Its commercial products include good tissue practice laboratory infrastructure, adipose-derived stem cells (ADSC) for regenerative medicine, and CIK and DC-CIK against cancers. The company also develops medicines for various types of cancers, cell immunotherapy, and stem cell regenerative therapy technologies.
Pell Bio-Med Technology Co., Ltd. Fundamentals Summary
6949 fundamental statistics | |
---|---|
Market cap | NT$6.12b |
Earnings (TTM) | -NT$403.74m |
Revenue (TTM) | NT$17.99m |
340.1x
P/S Ratio-15.2x
P/E RatioIs 6949 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6949 income statement (TTM) | |
---|---|
Revenue | NT$17.99m |
Cost of Revenue | NT$38.36m |
Gross Profit | -NT$20.37m |
Other Expenses | NT$383.37m |
Earnings | -NT$403.74m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -7.00 |
Gross Margin | -113.22% |
Net Profit Margin | -2,244.37% |
Debt/Equity Ratio | 0% |
How did 6949 perform over the long term?
See historical performance and comparison